Sai Parenterals Ltd

Sai Parenterals' Australian subsidiary, Noumed Pharmaceuticals, has renewed its exclusive Over-The-Counter (OTC) medicines supply agreement with leading Australian pharmacy networks. The landmark 7½-year deal is valued at AUD 202 million (approximately INR 1300 crores), with an option for a further 3-year extension. The agreement includes adding 12 new products annually, enhancing the contract's value and scope. This renewal strengthens Noumed's position as a strategic supply partner and expands Sai Parenterals' international footprint, ensuring predictable, recurring revenues and enhancing manufacturing scale. The deal underscores confidence in Noumed's regulatory, quality, and supply chain capabilities in a highly regulated market.

Sai Parenterals Ltd announced that its subsidiary, Noumed Pharmaceuticals Pty Limited, has entered into an exclusive OTC medicines supply agreement with Australia's leading pharmacy network. The contract is valued at Australian Dollars (AUD) 202 million, equivalent to INR 1300 crores, with an exchange rate of 1 AUD = INR 64.5. The agreement has an initial term of 7.5 years, with an option for a further 3-year extension upon mutual consent. The effective date for this contract is July 1, 2026. The company confirmed that promoters, promoter groups, or group companies have no interest in the awarding entity, and the transaction does not fall under related party transactions.

Sai Parenterals Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015 and the company's internal code of conduct. The window will be shut from July 1, 2026, until 48 hours after the declaration of the un-audited financial results for the quarter ending June 30, 2026. This restriction applies to all designated persons, their immediate relatives, and connected persons. The date of the board meeting to approve these financial results will be communicated separately.

Sai Parenterals Limited has secured a significant purchase order valued at USD 11 million (approximately ₹104.50 Crores) from PILL CORP, Bulacan, Philippines. The contract is for the exclusive supply of anti-TB products to the Philippines market for a period of ten years, commencing June 1, 2026. This long-term agreement is expected to generate periodic purchase orders throughout its duration. The company confirmed that there is no promoter or promoter group interest in the awarding entity, and the transaction does not fall under related party transactions. This order represents a substantial international business win for Sai Parenterals.

Sai Parenterals Ltd (SPL) announced its audited financial results for the quarter and year ended March 31, 2026. Q4 FY26 revenue stood at ₹197.93 crores, up 166.65% QoQ, with EBITDA at ₹28.97 crores (up 366.97% QoQ) and PAT at ₹13.25 crores (up 736.04% QoQ). FY26 revenue reached ₹380.99 crores, a 140.37% YoY increase, with EBITDA at ₹47.21 crores (up 33.29% YoY) and PAT at ₹14.37 crores (up 45.52% YoY). Standalone revenue for FY26 was ₹164.99 crores, up 30.65% YoY.

Sai Parenterals Ltd. announced the approval of audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, during a board meeting held on May 23, 2026. The board also approved the unaudited financial results and limited review report for the quarter and nine months ended December 31, 2025. M/s. R Kabra & Co. LLP issued an unmodified opinion on the audited financial results.

Sai Parenterals Ltd reports no deviations or variations in the utilization of proceeds from its Initial Public Offer (IPO) for the quarter and year ended March 31, 2026. This is in compliance with Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The IPO raised ₹2,850 million, and the funds were allocated to various objectives, including capacity expansion, R&D, debt repayment, working capital, and general corporate purposes. Monitoring agency M/s. India Ratings & Research Private Limited confirmed no deviations.

Sai Parenterals Ltd. announced its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The Board Meeting was held on May 23, 2026, where the results were approved. Standalone revenue from operations for the quarter ended December 31, 2025, stood at ₹384.79 million. The company also declared that the auditors issued an unmodified opinion on the audited financial results for the year ended March 31, 2026.

Sai Parenterals Ltd. approved the audited financial results (standalone and consolidated) for the quarter and year ended March 31, 2026, along with the unaudited financial results for the quarter and nine months ended December 31, 2025. The board meeting, held on May 23, 2026, also approved the limited review report and auditors' report with an unmodified opinion. The meeting concluded at 4:15 p.m.

Sai Parenterals Ltd has scheduled a Board of Directors meeting on May 23, 2026, to consider and approve the un-audited financial results for the quarter and nine months ended December 31, 2025, along with the limited review report. The board will also consider the audited financial results and audit report for the quarter and year ended March 31, 2026.